Idarubicin-transarterial chemoembolization combined with gemcitabine plus cisplatin for unresectable intrahepatic cholangiocarcinoma  

作　　者：Cheng-Hao Zhao Huan Liu Tao Pan Zhan-Wang Xiang Lu-Wen Mu Jun-Yang Luo Chu-Ren Zhou Ming-An Li Ming-Ming Liu Hu-Zheng Yan Ming-Sheng Huang 

机构地区：[1]Department of Interventional Radiology,Third Affiliated Hospital of Sun Yat-sen University,Guangzhou 510630,Guangdong Province,China [2]Department of Radiology,Third Affiliated Hospital of Sun Yat-sen University,Guangzhou 510630,Guangdong Province,China

出　　处：《World Journal of Gastrointestinal Oncology》2025年第4期81-92,共12页世界胃肠肿瘤学杂志(英文)

基　　金：Supported by the Guangzhou Science and Technology Plan Project,No.2023A04J0419;National Natural Science Foundation Cultivation Project at the Third Affiliated Hospital of Sun Yat-sen University,No.2022GZRPYQN04.

摘　　要：BACKGROUND Intrahepatic cholangiocarcinoma(iCCA)is the second most common liver malignancy with poor prognosis and limited treatment options.AIM To identify the most effective drug for transarterial chemoembolization(TACE)in cholangiocarcinoma and evaluate the efficacy and safety of combining it with gemcitabine and cisplatin(GemCis)for unresectable iCCA.METHODS Cholangiocarcinoma cell lines(RBE,HuCC-T1)were treated with 10 chemotherapeutic drugs,and cytotoxicity was assessed by cell counting kit-8 assays.Tumorbearing nude mice were treated with idarubicin or GemCis,and tumor growth was monitored.Clinical data from 85 iCCA patients were analyzed to evaluate the efficacy and safety of idarubicin-TACE combined with GemCis.RESULTS Idarubicin demonstrated the highest cytotoxicity,significantly outperforming GemCis,the standard first-line therapies.In tumor-bearing mouse models,idarubicin and GemCis treatments significantly slowed tumor growth,with idarubicin showing particularly pronounced effects on days 12 and 15(P<0.05).In retrospective analysis,the median overall survival(OS)and progression-free survival(PFS)in the combination therapy group were significantly longer than those in the GemCis alone group(median OS,16.23 months vs 10.07 months,P=0.042;median PFS,7.73 months vs 6.30 months,P=0.023).Additionally,major grade 3/4 adverse events(AEs)in the combination therapy group were abdominal pain(26.3%vs 6.5%,P=0.049)and elevated transaminases(42.1%vs 12.9%,P=0.038).Most AEs were mild to moderate and manageable.CONCLUSION Idarubicin demonstrated higher cytotoxicity than GemCis,significantly inhibiting tumor growth in tumor-bearing mouse models.Preliminary clinical results suggest that local idarubicin-TACE combined with GemCis may offer improved survival outcomes for iCCA patients with a manageable safety profile.

关 键 词：Transarterial chemoembolization Intrahepatic cholangiocarcinoma GEMCITABINE CISPLATIN IDARUBICIN 

分 类 号：R73[医药卫生—肿瘤]